53BP1基因在卵巢癌中的表达及其临床意义

Expression of 53BP1 in ovarian carcinoma and its clinical significance

目的:观察53BP1在不同类型卵巢癌(浆液性癌、透明细胞癌、子宫内膜样癌和黏液性癌)中的表达,探讨53BP1在卵巢癌中表达的临床意义。方法:应用免疫组化En Vision法研究157例卵巢癌(浆液性癌61例、透明细胞癌38例、子宫内膜样癌44例、黏液性癌14例)及65例正常卵巢组织中53BP1表达。结果:157例卵巢癌中,53BP1阳性表达者64例,阳性率为40.8%,而65例正常组织中,53BP1阳性率为70.8%,53BP1在卵巢癌组织中的阳性表达明显低于正常组织(P<0.01)。53BP1在不同类型卵巢癌中的阳性表达没有明显差异(P>0.05)。53BP1在卵巢Ⅱ型癌中的阳性表达高于Ⅰ型癌,但差异无统计学意义(P=0.058)。53BP1在卵巢癌Ⅲ、Ⅳ期的阳性表达虽低于Ⅰ、Ⅱ期,但无统计学差异(P>0.05)。结论:53BP1失表达可能参与了卵巢癌的发生。

Objective： To study the expression of 53BP1 in various ovarian carcinomas （serous carcinoma, clear cell carcinoma,endometrial carcinoma, and mucinous carcinoma） , and to explore the clinical significance of 53BP1 in ovarian carcinoma. Methods：Immunohistochemical EnVision method was used to detecte the expression of 53BP1 in 157 cases of ovarian carcinoma（61 cases of serous carcinoma,38 cases of clear cell carcinoma,44 cases of endometri- al carcinoma, 14 cases of mucinous carcinoma）and 65 cases of normal ovarian tissue. Results：In 157 cases of ovarian carcinoma,the positive expression cases of 53BP1 was 64 cases, the positive expression rate of 53BP1 was 40.8%. However, the positive expression rate of 53BP1 in 65 cases of normal tissue was 70. 8% （P 〈 0.01 ）. There was no sig- nificant difference of the positive expression of 53BP1 between serous carcinoma and mucinous carcinoma or between clear cell carcinoma and mucinous carcinoma（ P 〉 0.05 ）. 53BP1 expression in ovarian carcinoma of type Ⅱ was higher than that in type I with no significant difference（P =0. 058）. The positive expression rate of 53BPI in stage Ⅲ, Ⅳ was lower than those in stage Ⅰ , Ⅱ but no significant difference was seen（P 〉0.05）. Conclusion：The loss of 53BP1 expression may be involved in the carcinogenesis of ovarian carcinoma.